Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million

Summary by AI BETAClose X

Vivoryon Therapeutics N.V. successfully completed a private placement, raising EUR 5.1 million through the issuance of 3,380,500 new shares. The shares were priced at EUR 1.50 each and the placement was supported by both existing and new shareholders. This capital raise extends the company's cash runway well into Q3 2026. The company intends to use the proceeds to secure a strategic partnership for varoglutamstat in chronic kidney disease and for general corporate purposes. Following the offering, the number of outstanding shares will increase to 29,614,337, and the share capital will increase by EUR 33,805.00 to EUR 296,143.37.

Disclaimer*

UK 100

Latest directors dealings